
Analyst Jason McCarthy of Maxim Group maintained a Buy rating on Polaryx Therapeutics, Inc., with a price target of $10.00. Jason McCarthy’s rating is based on Polaryx’s progress toward launching
Compare up to 40 stocks
Compared Stocks: 1 / 40
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| PLYX | Polaryx Therapeutics, Inc. | 1.33 | -33.67 | -96.20% |
| Name | Price | % Change | |
|---|---|---|---|
| $1.33 | -96.20% |

Analyst Jason McCarthy of Maxim Group maintained a Buy rating on Polaryx Therapeutics, Inc., with a price target of $10.00. Jason McCarthy’s rating is based on Polaryx’s progress toward launching

Polaryx (PLYX) announced the activation of the first clinical trial site for SOTERIA, its Phase 2 basket trial evaluating the company’s lead investigational drug candidate, PLX-200, across four rare pediatric

Polaryx Therapeutics, Inc. ( ($PLYX) ) has shared an announcement. On August 27, 2026, Polaryx Therapeutics appointed pediatric endocrinologist Will Charlton as chief medical officer, effective September 1, 2026, adding

Polaryx (PLYX) announced the appointment of Will Charlton as chief medical officer, effective September 1. Prior to joining Polaryx, Charlton served as senior VP, clinical development, Skeletal Dysplasia at Tyra

Polaryx (PLYX) provided an operational readiness update for SOTERIA, its Phase 2 basket trial evaluating PLX-200 across four rare pediatric LSDs. Polaryx continues to advance clinical trial start-up activities in

Raymond James initiated coverage of Polaryx (PLYX) with a Strong Buy rating and $6 price target Polaryx is advancing PLX-200 into a Phase 2 basket trial across four rare pediatric

Lucid Capital initiated coverage of Polaryx (PLYX) with a Buy rating and $7 price target The company is PLYX developing disease-modifying therapies for rare pediatric lysosomal storage diseases, led by

Polaryx Therapeutics, Inc. ( ($PLYX) ) just unveiled an announcement. On July 19, 2026, Polaryx Therapeutics, Inc. announced the immediate resignation of its Chief Medical Officer, Lisa Bollinger, MD, marking

Polaryx Therapeutics, Inc. ( ($PLYX) ) has issued an announcement. On July 16, 2026, Polaryx Therapeutics, Inc.’s board set its 2026 annual meeting of stockholders to be held virtually on

H.C. Wainwright analyst Raghuram Selvaraju initiated coverage of Polaryx (PLYX) with a Buy rating and $7 price target PLX-200 uses a long-approved active ingredient and enters SOTERIA with preclinical evidence
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.